NGM Biopharmaceuticals, Inc. announced that two of current Class II directors, David Schnell, M.D. and McHenry T. Tichenor, Jr., who have served on the Board since January 2008 and March 2010, respectively, notified NGM on April 26, 2021 that they are resigning from the Board, effective upon the expiration of their respective terms at the 2021 Annual Meeting and are not standing for reelection.